Workflow
pembrolizumab (Keytruda)
icon
Search documents
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
Globenewswire· 2025-07-16 12:00
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune modulation. Headquartered in Boston, Massachusetts, we a ...
This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback
The Motley Fool· 2025-07-16 08:12
A few years ago, Pfizer (PFE -2.86%) was on top of the world when it came to earnings and stock price performance. The pharma giant recorded a record of $100 billion in sales back in 2022, and saw its shares rise 60% over nearly two years through a peak in late 2021. This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous levels of revenue. But as demand for those products waned in the later stages of the health crisis, Pfizer saw revenue drop significantly. T ...
Merus (MRUS) 2025 Conference Transcript
2025-05-15 16:40
Merus (MRUS) 2025 Conference May 15, 2025 11:40 AM ET Speaker0 Good morning. Welcome to the final, day of the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analysts at the firm. It's our pleasure to have with us, our next presenting company, Maris. Presenting from Maris this morning is CEO Bill Lindenberg. Bill, good morning. Thanks for flying to Las Vegas for us. Speaker1 Happy to be here. And let me also extend a great deal of thanks to you, to Zeen, and the e ...